Rifampin is essential for the short-course treatment of tuberculosis. But treating tuberculosis in HIV-infected persons is complicated by drug-drug interactions between rifampin and newer antiretroviral drugs, including the protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). However, rifabutin can be co-administered with many of these antiretrovirals. This article reviews data on the interactions of these drugs and suggests alternative regimens for treating tuberculosis in patients who need antiretroviral therapy with PIs or NNRTIs. 

[The AIDS Reader 10(2):102-108, 2000. © 2000 Cliggott Publishing Co., Division of SCP/Cliggott Communications, Inc.]